LL-37 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation. LL-37 is not fda-approved as therapeutic. research compound. derivatives in late-stage clinical trials. As with any research compound, individual responses vary.
Is LL-37 Safe?
Safety is the most important consideration with any research compound. LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide with a safety profile established through preclinical research.
Achieves 3+ log reduction of S. aureus biofilms within 5 minutes at therapeutic concentrations. A derivative (omiganan/ropocamptide) advanced to late-stage clinical trials for catheter-site infections. Multiple antimicrobial peptides in this class entering human trials.
What Are the Known Side Effects of LL-37?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
These effects are based on preclinical data and community reports at standard dosages of 100-500 mcg (topical/local application). Higher doses generally increase both the likelihood and severity of side effects.
Are LL-37 Side Effects Dose-Dependent?
Most reported LL-37 side effects are dose-dependent — meaning they're more likely at higher doses and less likely at the lower end of the 100-500 mcg (topical/local application) range.
This is why starting at the minimum effective dose and titrating up is the standard approach. With a half-life of rapidly degraded by proteases; major clinical limitation, any adverse effects will typically resolve within a few half-life periods after discontinuation.
What About Long-Term LL-37 Use?
Long-term safety data for LL-37 is limited, as with most research peptides. Standard cycles run acute use as needed.
LL-37 is not fda-approved as therapeutic. research compound. derivatives in late-stage clinical trials. Extended use beyond recommended cycles should be approached with caution.
Does LL-37 Interact With Other Compounds?
Pairs with BPC-157 for wound healing — LL-37 handles antimicrobial defense while BPC-157 promotes tissue repair.
When stacking peptides, be aware that combining multiple compounds increases the total side-effect surface area. Monitor closely when introducing any new compound.
How Can You Minimize LL-37 Side Effects?
Start at the lower end of the dosage range (100-500 mcg (topical/local application)). Use proper reconstitution and injection technique to minimize injection site reactions. Store correctly (lyophilized at -20°C, reconstituted at 2-8°C) to maintain purity.
Source only from vendors with third-party COA testing — contaminated or mislabeled products are a significant source of unexpected adverse effects.
What Is the Bottom Line on LL-37 Safety?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation. Overall, LL-37 is considered a compound requiring careful monitoring at standard research doses.
Read our LL-37 dosage guide for protocols designed to minimize risk.
Complete Guide
LL-37 : Benefits, Dosage, Side Effects & Research
Related Reading
- LL-37 Dosage Guide
- LL-37 Benefits
- LL-37 Stacking Guide
- LL-37 Cycle Guide
- LL-37 Research
- BPC-157 Complete Guide
Calculate Your LL-37 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for LL-37.
Open Calculator →Research-Grade Sourcing
If you're going to research LL-37, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What is the recommended LL-37 dosage?
Common dosages: 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal. Cycle length: acute use as needed. Half-life: rapidly degraded by proteases; major clinical limitation. Use our peptide calculator for exact reconstitution math.
What are the side effects of LL-37?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Is LL-37 safe?
LL-37 has shown a preliminary safety profile in research. Not FDA-approved as therapeutic. Research compound. Derivatives in late-stage clinical trials. All research should follow appropriate safety protocols.